Stopped: COVID restrictions prohibit further study activies
This open-label study will determine if chlorthalidone is safe and effective for the use of reducing urinary calcium excretion over 4 weeks in subjects with type 1 diabetes
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Urinary Calcium Excretion
Timeframe: Assessed at baseline and at 4 weeks
Hypokalemia
Timeframe: Assessed weekly for up to 4 weeks or until hypokalemia develops
Hypercalcemia
Timeframe: Assessed weekly for up to 4 weeks or until hypercalcemia develops
Hyperglycemia
Timeframe: Assessed at baseline and at 4 weeks